Association of Argatroban Dose With Coagulation Laboratory Test in Patients on Extracorporeal Membrane Oxygenation: Activated Clotting Time vs Activated Partial Thromboplastin Time.

Hyun-Young AhnYuju JungTae Wan KimYang Hyun ChoJeong Hoon YangChi Ryang ChungMyung-Sook MinRyoung-Eun Ko

Published in: The Annals of pharmacotherapy (2023)

A weak correlation was observed between argatroban dose and the aPTT and ACT values. However, the agreement between aPTT and ACT was only 46.1% regarding the scope of target range. Further research is necessary to determine how to assess the optimal argatroban dose for patients administered argatroban while undergoing ECMO at the intensive care unit.

Keyphrases

extracorporeal membrane oxygenation
end stage renal disease
ejection fraction
newly diagnosed
acute respiratory distress syndrome
chronic kidney disease
peritoneal dialysis
patient reported outcomes
intensive care unit